NASDAQ:BCAX
Bicara Therapeutics Inc.
Bicara Therapeutics Inc. reported net income of −$137.9M in fiscal 2025. Free cash flow was −$107.1M, and the diluted share count rose 225.4%.Summary generated from Bicara Therapeutics Inc.'s SEC filings. Latest annual report filed Mar 30, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−30.9%
Debt / equityn/a
Free cash flow−$107.1M
FCF marginn/a
Share count change+225.4%
Financials
| Item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | n/a | n/a | n/a |
| Operating income | −40 | −82 | −156 |
| Net income | −52 | −68 | −138 |
| Free cash flow | −46 | −75 | −107 |
Recent filings
- 4Insider transaction report
Sep 10, 2026 - 8-KEntry into a material agreement
Aug 25, 2026 - 4Insider transaction report
Aug 14, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 11, 2026 - 8-KResults of operations and financial condition
Aug 11, 2026 - 8-KDirector or officer change
Jul 28, 2026 - 8-KResults of a shareholder vote
Jun 10, 2026 - 8-KOther events
May 21, 2026